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1 The antithrombotic eect of the glycoprotein IIb/IIIa receptor antagonist, CRL42796, was
examined in canine models of carotid and coronary artery thrombosis.
2 In the carotid artery thrombosis model, occlusion occurred in all control vessels (time to
thrombosis 47.6+8.9 min). After treatment with low dose CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.), two of ®ve vessels occluded. Time to thrombosis increased signi®cantly
to 155.2+23.1 min. When the drug infusion was increased (0.69 mg kg71 min71), each of ®ve vessels
remained patent.
3 Ex vivo platelet aggregation in response to arachidonic acid (AA) and ADP was examined in
platelet rich plasma (PRP) prepared from citrate or heparin anticoagulated blood. CRL42796
reduced platelet reactivity at low and high doses in PRP from citrate anticoagulated blood.
However, in PRP from heparin anticoagulated blood, only the higher infusion dose produced a
signi®cant reduction in ex vivo platelet responses.
4 A combination of oral aspirin (4.6 mg kg71 741, 717 h) and the low infusion dose of
CRL42796 did not produce an additional bene®t beyond that provided by CRL42796 alone.
5 Coronary artery thrombosis was inhibited in four of ®ve vessels treated with the lower infusion
dose of CRL42796 and in ®ve of ®ve vessels treated with the higher infusion. Time to thrombosis
increased with both doses (Control, 90.8+10.4 min; low dose, 165.8+14.2 min; high dose,
4180.0+0 min).
6 The results indicate that CRL42796 is an eective in vivo antithrombotic agent against
experimentally-induced carotid and coronary artery thrombosis.
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Introduction
Accepted approaches to the management of patients
presenting with an evolving myocardial infarction involve
the use of angioplasty or thrombolytic therapy (streptokinase,
activase, retavase, etc.) coadministered with both heparin and
acetylsalicylic acid (aspirin) (Gensini et al., 1999; Gibson,
1999; Spinler et al., 2001). Whereas either angioplasty or
administration of a thrombolytic agent is eective in
restoring arterial blood ¯ow, maintaining vessel patency
depends upon adjunctive therapy directed at inhibition of
thrombin generation and/or platelet reactivity. Several
antiplatelet agents (abciximab, epti®batide, tiro®ban, ticlopi-
dine, clopidogrel), having mechanisms of action diering
from that of aspirin, show ecacy in reducing the incidence
of thrombotic occlusion after restoration of arterial blood
¯ow (Spinler et al., 2001).
Platelets serve an important role in arterial thrombosis and
represent a predominant pharmacologic target for the
prevention of reocclusion after successful recanalization of
an occluded vessel. Although aspirin can modulate platelet
reactivity, its antiplatelet potential is achieved as a result of
inhibition of cyclo-oxygenase, essential for conversion of
arachidonic acid to thromboxane A2. The latter serves as a
platelet activator and arterial vasoconstrictor. Aspirin is
eective in preventing ex vivo arachidonic acid-induced
platelet aggregation, but lacks signi®cant antiaggregatory
ecacy against other platelet agonists (5-HT, epinephrine,
thrombin, plasmin, etc.). On the other hand, pharmacologic
interventions directed against the platelet glycoprotein (GP)
IIb/IIIa receptor are eective antiaggregatory agents regard-
less of the inciting agonist (Makkar et al., 1997).
The present study was designed to evaluate a new platelet
GPIIb/IIIa receptor antagonist, CRL42796, for its anti-
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thrombotic ecacy. Studies also were designed to explore the
minimal eective dose of CRL42796 in combination with
aspirin. Anaesthetized canines were subjected to electrolytic
injury of the carotid or coronary arteries for induction of
primary arterial thrombosis. The latter is de®ned as an
occlusive thrombus secondary to arterial wall injury. Previous
studies in our laboratory demonstrated that GPIIb/IIIa
receptor antagonists are eective in preventing primary
thrombus formation and maintaining vessel patency (Mick-
elson et al., 1990; Rote et al., 1994a). Ex vivo platelet
aggregation and bleeding times were measured. The results
demonstrate that CRL42796 is an eective antithrombotic
agent with a minimal tendency to induce signi®cant
uncontrolled bleeding.
Methods
Guidelines for the use and care of experimental animals
The procedures used in this study are in accordance with the
guidelines of the University of Michigan University
Committee on the Use and Care of Animals and conform
to the standards in The Guide for Care and Use of
Laboratory Animals (NIH no. 86 ± 23). The University of
Michigan Unit for Laboratory Animal Medicine provided
veterinary care.
Surgical preparation and model of vessel occlusion
Purpose-bred hound dogs, weighing 9 ± 12 kg, were anaes-
thetized with sodium pentobarbital (30 mg kg71, i.v.). The
animals were intubated and ventilated with room air using a
Harvard respirator (Harvard Apparatus, Inc., Holliston, MA,
U.S.A.), adjusted to deliver a tidal volume of 30 ml kg71 at a
frequency of 12 breaths min71. A catheter was inserted into
the right and left femoral veins for drug administration and
blood sampling. Arterial blood pressure was recorded from
the right femoral artery using a Millar2 Mikro-tip catheter
(Millar Instruments, Inc., Houston, TX, U.S.A.). A standard
limb lead II electrocardiograph was recorded continuously to
monitor heart rate. A calibrated ultrasonic ¯ow probe
(Model 2RB907, Transonic Systems Inc., Ithaca, NY,
U.S.A.) was placed on the carotid artery and blood ¯ow
was monitored continuously. All physiologic parameters were
recorded on a Grass polygraph interfaced to a MacLab (AD
Instruments Pty Ltd, Castle Hill, Australia) data acquisition
system and Macintosh2 computer (Apple Computer, Inc.,
Cupertino, CA, U.S.A.).
An intravascular electrode was inserted through the wall
of the carotid artery and positioned so that the non-
insulated intraluminal portion of the electrode was in ®rm
contact with the intimal surface of the vessel. An external
adjustable constrictor was applied to the artery. The
intravascular electrode and mechanical constrictor were
positioned distal with respect to the ¯ow probe. The
mechanical constrictor on the carotid artery was constructed
of stainless steel, shaped to ®t around the vessel. A nylon
screw (2 mm in diameter) threaded through the C-shaped
metal band was adjusted to decrease the circumference of
the vessel thereby forming a regional stenosis. The vessel
was narrowed to a point where the pulsatile ¯ow pattern
was reduced by 50% without altering the mean carotid
artery blood ¯ow.
Electrolytic injury to the intimal surface of the carotid
artery was accomplished with the use of an intravascular
electrode composed of a Te¯on-insulated, silver-coated,
copper wire. Penetration of the vessel wall by the electrode
was facilitated by attaching the tip of a 25-gauge hypodermic
needle to the distal, non-insulated part of the electrode. The
intravascular electrode was connected to the positive pole
(anode) of a dual-channel square wave generator (Grass S88
stimulator and a Grass Constant Current Unit, Model
CCU1A). The cathode was connected to a distant sub-
cutaneous site. The current delivered to the vessel was
monitored continuously on an ammeter and maintained at
300 mA for induction of carotid artery vessel wall injury, and
150 mA when used to induce deep vessel wall injury in the
coronary artery. The anodal electrode was positioned to have
the non-insulated portion (3 ± 4 mm) in intimate contact with
the endothelial surface of the vessel. Proper positioning of the
electrode in the vessel and evidence of vessel wall injury was
con®rmed by visual inspection at the conclusion of each
experiment. The presence of the external constrictor results in
localized turbulent ¯ow and mimics the presence of an
atheromatous plaque in a diseased vessel. The combined
presence of deep vessel wall injury and turbulent ¯ow leads to
the progression of platelet-dependent occlusive thrombus
formation. The anodal current was terminated 30 min after
arterial occlusion as indicated by the absence of blood ¯ow.
On the other hand, the anodal injury current was maintained
for a maximum duration of 3 h if the vessel remained patent
as evidenced by the presence of blood ¯ow after which the
anodal current was suspended. In the latter instance, a value
of 180 min was used as the `time to occlusive thrombosis' for
the purpose of statistical analysis.
Model of coronary artery thrombosis
The heart was exposed through a left thoracotomy at the
sixth intercostal space and suspended in a pericardial cradle.
A 1-cm segment of the left circum¯ex (LCX) coronary artery
was exposed proximal to the ®rst obtuse marginal branch and
instrumented with a Transonic2 ultrasonic ¯ow probe
(Model 1.5RB, Transonic Systems Inc., Ithaca, NY,
U.S.A.) for continuous monitoring of phasic coronary artery
blood ¯ow. Instrumentation of the canine coronary artery for
induction of arterial thrombosis was similar to that described
for the carotid artery. A ligature stenosis was placed around
the LCX coronary artery such that the hyperemic response to
a 10-s occlusion was reduced by 30%. Mean coronary artery
blood ¯ow was not aected by the stenosis. An intracoronary
electrode was inserted through the LCX arterial wall so that
the uninsulated portion was positioned against the endothe-
lial surface. Deep vessel wall injury and occlusive arterial
thrombosis was initiated via application of an anodal current
(150 mA) to the intimal surface of the vessel.
Experimental protocol
Initially, the carotid artery was selected for our experimental
model as it allows one vessel (the right carotid artery) to be
used as a control and the other (the left carotid artery) to be
used as a test vessel after the administration of CRL42796.
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Previous studies have validated the 2-vessel model of
thrombosis (Rote et al., 1993; 1994b). The intravenous
administration of 0.9% sodium chloride solution for injection
served as the placebo control, administered as a loading dose
followed by a continuous infusion for 180 min. The placebo
was administered 45 min before initiation of electrolytic
injury in the right carotid artery. CRL42796 was adminis-
tered intravenously as a loading dose of 15 mg kg71 followed
by an infusion of 0.31 mg kg71 min71 or 0.69 mg kg71 min71
for 180 min. The anodal current was applied to the left
carotid artery 45 min after initiating the administration of
CRL42796. The anodal injury current was applied for a
period not to exceed 3 h. If the vessel occluded before the 3 h
time point, the current was discontinued 30 min after ¯ow in
the vessel ceased. Time to occlusion was recorded. If a vessel
did not occlude by 3 h, as occurred in the presence of
CRL42796, the anodal current was discontinued and a value
of 180 min was used for the purpose of statistical
comparison.
Thrombus weight was determined after removal of the
intact thrombus from the vessel wall. Ex vivo platelet
aggregation determinations and tongue bleeding times were
recorded at baseline, after completing the surgical prepara-
tion, 120 min and 225 min after placebo or drug administra-
tion. Heart rate, mean arterial blood pressure and phasic
arterial blood ¯ow were recorded continuously.
In a separate group of experiments, aspirin was adminis-
tered orally at a dose of 4.6 mg kg71, 41 h and 17 h before
the initiation of electrolytic injury of the vessel wall to assess
the eects of combining low dose aspirin with CRL42796.
Previous studies demonstrated that the aspirin dosing regi-
men mimics low dose aspirin and signi®cantly increases time
to arterial thrombosis (Hennan et al., 2001). The left carotid
artery was subjected to deep vessel wall injury in the presence
of low dose aspirin alone and the right carotid artery was
subjected to deep vessel wall injury in the presence of a
combination of low dose aspirin and CRL42796 (15 mg kg71
loading dose +0.31 mg kg71 min71).
A similar experimental protocol to that described above
was used to assess the eect of CRL42796 on prevention of
LCX coronary artery thrombosis except separate groups of
animals acted as controls and drug-treatments. Group 1
served as controls (saline-treated i.v.), Group 2 was treated
with CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.) and Group 3 was treated with
CRL42796 (15 mg kg71 loading dose +0.69 mg kg71 min71
i.v.). Haematological values were obtained at baseline,
120 min and 225 min after placebo or drug administration.
Haematological measurements
Ex vivo platelet aggregation Blood (10 ml) was withdrawn
from the right femoral vein into a plastic syringe containing
3.7% sodium citrate as the anticoagulant (1 : 10 citrate to
blood; v v71). Platelet rich plasma (PRP) was obtained by
collecting the supernatant from whole blood centrifuged at
1406g for 5 min. Subsequently, platelet poor plasma (PPP)
was prepared from the same blood sample by further
centrifugation at 20006g for 10 min. Ex vivo platelet
aggregation was assessed at 378C with a four-channel platelet
aggregometer (Bio-Data-PAP-4, Bio Data, Hatboro, PA,
U.S.A.) by recording the increase in light transmission
through a stirred suspension of PRP adjusted to 200,000
platelets ml71. Aggregation was induced with arachidonic acid
(AA, 650 mM) or ADP (20 mM). A subaggregatory dose of
epinephrine (550 nM) was used to prime the platelets before
the agonists were added.
Tongue-template bleeding time Bleeding times were deter-
mined with the use of a Surgicutt device (International
Technidyne Corporation, Edison, NJ, U.S.A.), that made a
uniform incision 5 mm long and 1 mm deep on the upper
surface of the tongue. The lesion was blotted with ®lter paper





amino}propanoic acid dihydrochloride was supplied by
Laboratoire L. Lafon (Maisons Alfort, France) and dissolved
in 0.9% sodium chloride solution for injection. The chemical
structure is shown in Figure 1. All remaining reagents were
purchased from Sigma Chemical Co. (St. Louis, MO,
U.S.A.).
Statistical analysis
The data are expressed as mean+s.e.m. Comparisons among
the incidence of carotid or coronary artery occlusion in saline
and drug-treated dogs were performed using a w2 test.
Changes in time to carotid or coronary artery thrombosis
and thrombus weights between saline- and drug-treated
animals were carried out using paired t-tests. Changes in
time to thrombosis among saline-treated, aspirin-treated and
aspirin plus CRL42796-treated animals were made using a
one-way ANOVA followed by Student-Newman-Keuls multi-
ple comparison test. Platelet aggregation values and bleeding
times were compared to respective baseline values using a
one-way ANOVA followed by Dunnet's post hoc analysis.
P50.05 was considered statistically signi®cant for all
comparisons.
Figure 1 The chemical structure of CRL42796, (2S)-2-[(2-naphthyl-
sulfonyl)amino]-3-{[2-({4-(4-piperidinyl)-2-[2-(4 piperidinyl)ethyl]bu-
tanoyl}amino)acetyl]amino} propanoic acid, dihydrochloride.
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Results
Heart rate and mean arterial blood pressure were not
dierent among treatment groups before administration of
CRL42796. The intravenous administration of either
CRL42796 or vehicle (0.9% sodium chloride solution) did
not result in signi®cant dierences in heart rate and blood
pressure compared to respective controls during electrolytic
injury of the carotid or coronary artery (data not shown).
The eects of CRL42796 on the incidence of carotid artery
thrombosis and time to occlusive thrombus development are
shown in Table 1. The intravenous administration of
CRL42796 (15 mg kg71 loading dose +0.31 mg kg71 min71)
inhibited the development of occlusive thrombosis in 3/5 dogs
studied and signi®cantly increased time to thrombosis
compared to saline-treated controls (CRL42796,
155.2+23.1 min; control, 47.6+8.9 min). Increasing the
infusion dose of CRL42796 to 0.69 mg kg71 min71 completely
inhibited the development of occlusive thrombosis over the
180 min of electrolytic vessel wall injury (see Table 1).
Thrombus weight did not dier signi®cantly between controls
and animals receiving an infusion of CRL42796 at a rate of
0.31 mg kg71 min71. However, when the infusion dose was
increased to 0.69 mg kg71 min71 a signi®cant decrease in
thrombus weight was observed. The decrease in thrombus
weight was consistent with the observation that each of the
®ve vessels treated with the higher infusion dose of
CRL42796 remained patent after 180 min of electrolytically
induced vessel wall injury.
In animals pre-treated with aspirin (4.6 mg kg71) 41 and
17 hs before initiation of electrolytic injury, time to carotid
artery thrombosis was increased signi®cantly
(131.0+10.7 min) compared to saline-treated controls
(47.6+8.9 min) (see Table 1). Despite an increase in the
time to thrombosis, aspirin did not prevent the development
of an occlusive carotid artery thrombus in any of the ®ve
animals tested. When CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.) was combined with low dose
aspirin, three of the ®ve vessels tested did not occlude during
180 min of electrolytic injury. It is notable that similar results
were observed in the absence of low dose aspirin (see Table
1). Therefore, it appears that combining low dose aspirin with
CRL42796 does not provide additional protection against the
development of occlusive arterial thrombosis. Low dose
aspirin or a combination of low dose aspirin and
CRL42796 did not produce a signi®cant change in thrombus
weight compared to respective controls.
Figure 2 illustrates the carotid artery blood ¯ow in control
or CRL42796-treated animals during induction of vessel wall
injury. Time zero on the graph represents the initiation of the
anodal current for induction of deep vessel wall injury. As
indicated in Figure 2a, control animals exhibited a
progressive decline in carotid artery blood ¯ow to zero.
The latter was accompanied by the development of an
occlusive thrombus. In the presence of CRL42796
(15 mg kg71 loading dose +0.31 mg kg71 min71 i.v.) a
progressive decrease in blood ¯ow was observed during
electrolytic injury, however three of the ®ve carotid arteries
remained patent throughout the 180 min duration of anodal
current application. When the intravenous infusion of
CRL42796 was increased to 0.69 mg kg71 min71 the carotid
artery blood ¯ow remained relatively stable during applica-
tion of the electrolytic injury current and all vessels were
patent at the end of 180 min at which point the anodal
current was terminated (see Figure 2b).
When aspirin (4.6 mg kg71 741, 717 h p.o.) was
combined with CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.) carotid artery blood ¯ow de-
creased progressively during electrolytic injury. However,
despite the addition of aspirin to the treatment regimen only
three of the ®ve vessels studied remained patent over the
course of the experiment (see Figure 2c).
The eect of CRL42796 on platelet aggregation in response
to ADP (20 mM) and arachidonic acid (AA, 650 mM) from
citrated whole blood is shown in Figure 3. At doses of
15 mg kg71 loading dose +0.31 mg kg71 min71 i.v. (Figure
3a) and 15 mg kg71 loading dose +0.69 mg kg71 min71 i.v.
(Figure 3b), CRL42796 signi®cantly reduced ex vivo platelet
responses to both ADP and AA. When animals were
pretreated with aspirin (4.6 mg kg71 741, 17 h p.o.), platelet
responses to AA were inhibited at baseline indicating
inhibition of platelet COX-1. In contrast, platelet responses
to ADP were unchanged (see Figure 3c). As anticipated, the
addition of CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.) signi®cantly reduced, but did not
prevent, ex vivo platelet responses to ADP in aspirin-treated
dogs, whereas ex vivo platelet responses to AA remained
inhibited over the course of the experimental protocol.
Selected experiments were conducted to determine if
platelet responses are altered by the use of citrate as an
Table 1 Incidence of carotid artery occlusion and time to thrombosis after intravenous administration of CRL42796
Carotid artery occlusion Carotid artery time to thrombosis Thrombus weight
Treatment (incidence) (%) (min) (mg)
Saline (loading dose+infusion i.v.) 5/5 (100) 47.6+8.9 20.2+4.1
CRL42796 (15 mg kg71 loading dose+
0.31 mg kg71 min71 i.v.)
2/5 (40) 155.2+23.1* 27.6+6.6
Saline (loading dose+infusion i.v.) 5/5 (100) 47.2+6.5 27.5+1.4
CRL42796 (15 mg kg71 loading dose+
0.69 mg kg71 min71 i.v.)
0/5 (0)* 180.0+0* 6.1+1.7*
Aspirin (4.6 mg kg71 741, 717 h p.o.)
Saline (loading dose+infusion i.v.)
5/5 (100) 131.0+10.7* 22.2+5.2
Aspirin (4.6 mg kg71 741, 717 h p.o.)
CRL42796 (15 mg kg71 loading dose+
0.31 mg kg71 min71 i.v.)
2/5 (40) 154.6+16.2* 18.8+3.3
Data represent mean+s.e.mean for n=5 experiments. *Indicates a signi®cant dierence from respective saline control (P50.05).
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anticoagulant. Platelet responses to ADP and AA were
assessed under conditions in which venous blood for the
preparation of PRP and PPP was collected in syringes in
which heparin served as the anticoagulant. Figure 4a
illustrates the eects of CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.) on platelet aggregation in response
to AA and ADP when heparin was the anticoagulant. The
platelet aggregation responses were reduced in the presence of
the lower dose of CRL42796, however the changes were not
statistically signi®cant. At the higher dose of CRL42796, a
signi®cant reduction in ex vivo platelet reactivity was
observed. In aspirin-treated animals (4.6 mg kg71 741,
717 h p.o.), the use of heparin as an anticoagulant produced
similar results as observed with citrate. AA-induced platelet
aggregation was inhibited signi®cantly at baseline compared
to non-aspirin treated controls and remained inhibited
throughout the experimental protocol. ADP-induced platelet
aggregation in aspirin-treated dogs was similar at baseline
with heparin as the anticoagulant and the addition of
CRL42796 signi®cantly reduced platelet reactivity (see Figure
4c).
The eects of CRL42796 on tongue bleeding time are
shown in Figure 5. At the lower infusion dose of CRL42796
there was a trend towards an increase in tongue bleeding
time; however, the change was not statistically signi®cant
from baseline (Figure 5a). When the infusion dose of
CRL42796 was increased to 0.69 mg kg71 min71, there was
a related signi®cant increase in tongue bleeding time at 120
and 240 min after initiating the drug infusion (see Figure 5b).
Bleeding times exceeding 10 min were recorded as 10 min for
statistical analysis.
Aspirin (4.6 mg kg71 741, 717 h p.o.) did not produce a
signi®cant increase in bleeding time at baseline compared to
non-treated control animals (Figure 5c). The combination of
aspirin and CRL42796 (15 mg kg71 loading dose
+0.31 mg kg71 min71 i.v.) did not induce an increase in
bleeding time.
The eects of CRL42796 on the incidence of left circum¯ex
coronary artery thrombosis and time to occlusive thrombus
development are shown in Table 2. At an intravenous dose of
15 mg kg71 loading dose +0.31 mg kg71 min71 infusion,
CRL42796 inhibited the development of occlusive thrombosis
in 4/5 dogs and signi®cantly increased time to thrombosis
compared to saline-treated controls (CRL42796,
165.8+14.2 min; control, 90.8+10.4 min). Increasing the
infusion dose to 0.69 mg kg71 min71 completely inhibited
the development of occlusive thrombosis over the 180 min
period of electrolytic vessel wall injury (see Table 2).
Thrombus weight was not signi®cantly dierent among
control and CRL42796-treated animals.
The in vivo antithrombotic eects of CRL42796 were
examined in the canine coronary artery subjected to deep
vessel wall injury. The blood ¯ow results are summarized in
Figure 6. In the control group (n=5), coronary artery blood
¯ow decreased progressively commencing with the induction
of electrolytic injury of the vessel wall. Occlusive thrombosis
developed in each of the vessels within 90.8+10.4 min. Two
separate groups of ®ve animals each received CRL42796
commencing before induction of vessel wall injury. As before,
the drug was administered as an intravenous loading dose of
15 mg kg71 followed by an infusion of either
0.31 mg kg71 min71 (n=5) or 0.69 mg kg71 min71 (n=5). As
indicated in Table 2, one of ®ve vessels occluded in the group
receiving the low infusion dose whereas all vessels remained
patent in the group given the high infusion dose. Although all
vessels remained patent in the high infusion dose group, the
time to occlusion is listed in Table 2 as 180+0 min for the
purpose of statistical analysis.
Occlusive and non-occlusive thrombi were found in the
injured coronary arteries. In the saline-treated control group,
occlusive thrombi were present in each of the ®ve arteries and
®rmly attached to the site of vessel injury. One of ®ve vessels
Figure 2 Carotid artery blood ¯ow during electrolytic injury in the
absence and presence of CRL42796 (15 mg kg71+
0.31 mg kg71 min71 i.v.) (a); (15 mg kg71+0.69 mg kg71 min71 i.v.)
(b); and a combination of aspirin (4.6 mg kg71 741, 717 h p.o.
+15 mg kg71+0.31 mg kg71 min71 i.v.) (c). Deep vessel wall injury
was initiated at time 0 and produced complete and persistent
occlusion of all control carotid arteries. CRL42796 maintained
carotid artery patency in all vessels for the duration of the infusion
at a dose of 0.69 mg kg71 min71 i.v. and in three of ®ve vessels at a
dose of 0.31 mg kg71 min71 i.v. The combination of aspirin and the
lower infusion dose of CRL42796 produced no additional bene®t.
Values are mean+s.e.m for n=5 experiments.
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in the low dose infusion group showed the presence of an
occlusive thrombus while occlusive thrombi were not found
in any of the vessels in the high dose infusion group. The
thrombus weights did not dier among the groups despite the
fact that control vessels occluded whereas nine of ten vessels
from the animals treated with CRL42796 remained patent.
The apparent discrepancy between thrombus weight and
vessel patency relates to the fact that ¯ow was preserved in
the presence of the antiplatelet agent. Inhibition of the
platelet GPIIb/IIIa receptor prevents the formation of an
occlusive platelet plug and results in a thrombus mass that
extends in a retrograde direction without occluding the vessel
lumen. Prolongation in the time to thrombosis or its
prevention provides an extended period over which the `tail'
of the thrombus can propagate before the experiment is
terminated. In the control group, platelet accretion results in
the rapid formation of a ®rm, occlusive platelet plug with
little opportunity for extension beyond the site of vessel wall
injury before ¯ow declines to zero at which point the vessel is
removed for determination of thrombus weight.
Ex vivo platelet responses in citrated whole blood from the
coronary artery thrombosis protocol are shown in Figure 7.
PRP prepared from blood of control (saline-treated) dogs
showed typical ex vivo aggregation responses to AA (Figure
7a) or ADP (Figure 7b) over the entire time course of the
experimental protocol. Treatment with CRL42796 signi®-
cantly reduced platelet responses to both AA and ADP at
120 and 225 min after administration CRL42796 in both the
high and low dose regimens (see Figure 7). Ex vivo platelet
aggregation determinations also were performed with heparin
as the anticoagulant. As shown in Figure 8, ex vivo platelet
responses to AA (Figure 8a) and ADP (Figure 8b) were
reduced after administration of CRL42796 compared to
Figure 3 Eect of intravenous administration of CRL42796 on
citrated ex-vivo platelet aggregation induced by AA (650 mM) and
ADP (20 mM) during electrolytic injury to the carotid artery.
CRL42796 was administered as a loading dose of 15 mg kg71
followed by either 0.31 mg kg71 min71 (a) or 0.69 mg kg71 min71
(b). In (c), the eect of combining aspirin (4.6 mg kg71 741, 717 h
p.o.) with the lower infusion dose of CRL42796 are shown. Values
are expressed as mean+s.e.m for n=5 experiments. Asterisks
indicate a signi®cant reduction in platelet responses compared to
respective baseline (P50.05).
Figure 4 Eect of intravenous administration of CRL42796 on
heparinized ex-vivo platelet aggregation induced by AA (650 mM) and
ADP (20 mM) during electrolytic injury to the carotid artery.
CRL42796 was administered as a loading dose of 15 mg kg71
followed by either 0.31 mg kg71 min71 (a) or 0.69 mg kg71 min71
(b). In (c), the eect of combining aspirin (4.6 mg kg71 741, 717 h
p.o.) with the lower infusion dose of CRL42796 are shown. Values
are expressed as mean+s.e.m for n=5 experiments. Asterisks
indicate a signi®cant reduction in platelet responses compared to
respective baseline (P50.05).
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baseline; however not all measures were signi®cantly dierent
from baseline as was observed with citrated PRP.
The eects of CRL42796 on bleeding time during the
coronary artery thrombosis experiments are shown in Figure
9. After a loading dose of CRL42796 (15 mg kg71), infusion
doses of 0.31 mg kg71 min71 and 0.69 mg kg71 min71 in-
creased tongue bleeding time signi®cantly compared to non-
treated controls. The increase in bleeding time was similar at
120 min and 225 min after initiation of the infusion.
Discussion
The experimental model of arterial thrombosis used in this
study was validated previously (Romson et al., 1980; Rote et
al., 1993; 1994b). The unique feature of the model is that
arterial thrombosis develops spontaneously in response to
deep vessel wall injury. The latter is the dominant in¯uence
and by itself can lead to thrombosis. The vascular injury is
induced by an anodal current applied to the endothelial
surface of the vessel resulting in exposure of subendothelial
collagen and other components capable of increasing platelet
reactivity and subsequent activation of the coagulation
cascade. The development of a deep arterial wall lesion and
exposure of subendothelial structures allows the previously
nonthrombotic vascular surface to become prothrombotic.
The imposition of a critical stenosis immediately distal to the
site of vessel wall injury contributes to the thrombotic process
by increasing the degree of turbulence. The disruption in the
normal pattern of blood ¯ow further impairs endothelial
function and forms countercurrents and local pockets of
stasis. Turbulence and stasis disrupt the normal pattern of
laminar ¯ow thereby allowing platelets to encounter the
prothrombotic surface of the injured vessel wall. Within a
brief period after endothelial injury, platelets begin to form a
monolayer at the site where subendothelial elements
encounter the ¯owing blood. Subsequently the progressive
accretion of platelets, formation of ®brin and entrapment of
cellular blood components leads to the development of a
platelet-rich thrombus supported by a ®rm ®brin network
(Romson et al., 1980; Bush & Shebuski, 1990). A detailed
electron-microscopic examination of the electrolytically-in-
duced vessel wall injury and cellular composition of the
thrombus, plus the bene®ts derived from inhibition of in vivo
platelet reactivity has been published (Romson et al., 1980).
Many experimental models have been used for the study of
antithrombotic drugs (Bush & Shebuski, 1990). In the
electrolytic injury model, development of an occlusive
thrombus proceeds spontaneously in response to vessel wall
injury. The ability to control the size of the injured area, plus
the intensity and duration of the electrolytic anodal current,
make the model highly reproducible and dependent upon
natural physiological processes that lead to thrombus
formation. The interaction between the injured vessel wall
Figure 5 Eect of CRL42796 on tongue bleeding time at baseline,
after surgery, and 120 min and 225 min after intravenous adminis-
tration of drug. CRL42796 was administered as a loading dose of
15 mg kg71 followed by either 0.31 mg kg71 min71 (a) or
0.69 mg kg71 min71 (b). In (c), the eect of combining aspirin
(4.6 mg kg71 741, 717 h p.o.) with the lower infusion dose of
CRL42796 are shown. Values are expressed as mean+s.e.m for n=5
experiments. Asterisks indicate a signi®cant increase in bleeding time
compared to respective baseline (P50.05).
Table 2 Incidence of left circum¯ex coronary artery occlusion and time to thrombosis after treatment with CRL42796
Coronary artery occlusion Carotid artery time to thrombosis Thrombus weight
Treatment (incidence) (%) (min) (mg)
Control (saline+infusion i.v.) 5/5 (100) 90.8+10.4 8.8+2.3
CRL42796
(15 mg kg71+0.31 mg kg71 min71 i.v.)
1/5 (20)* 165.8+14.2* 7.9+2.6
CRL42796
(15 mg71 kg+0.69 mg kg71 min71 i.v.)
0/5 (0)* 180.0+0* 12.4+0.9
Data represent mean+s.e.mean for n=5 or 6 experiments. *Indicates a signi®cant dierence from saline-treated control (P50.05).
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and the circulating blood components are similar to those
pathophysiologic mechanisms that participate in the forma-
tion of occlusive thrombi in humans with vascular disease.
The ability to better approximate the pathophysiologic events
Figure 6 Left circum¯ex coronary artery blood ¯ow during
electrolytic injury. Deep vessel wall injury resulted in thrombotic
occlusion of all control vessels. Administration of CRL42796
maintained vessel patency in all vessels treated with a 15 mg kg71
loading dose followed by a 0.69 mg kg71 min71 i.v. infusion and in
four of ®ve vessels treated with the lower infusion dose of
0.31 mg kg71 min71 i.v. Values are expressed as mean+s.e.m for
n=5 or six experiments.
Figure 7 Eect of intravenous administration of CRL42796 on
citrated platelet responses to AA (650 mM) (a) and ADP (20 mM) (b)
during electrolytic injury to the left circum¯ex coronary artery.
CRL42796 was administered as a loading dose of 15 mg kg71
followed by either 0.31 mg kg71 min71 (a) or 0.69 mg kg71 min71
(b). Values are expressed as mean+s.e.m for n=5 or six experiments.
Asterisks indicate a signi®cant reduction in platelet responses
compared to respective baseline (P50.05).
Figure 8 Eect of intravenous administration of CRL42796 on
heparinized platelet responses to AA (650 mM) (a) and ADP (20 mM)
(b) during electrolytic injury to the left circum¯ex coronary artery.
CRL42796 was administered as a loading dose of 15 mg kg71
followed by either 0.31 mg kg71 min71 (a) or 0.69 mg kg71 min71
(b). Values are expressed as mean+s.e.m for n=5 or six experiments.
Asterisks indicate a signi®cant reduction in platelet responses
compared to respective baseline (P50.05).
Figure 9 Eect of CRL42796 on tongue bleeding time at baseline
and 120 min and 225 min after intravenous administration of drug
during electrolytic injury to the left circum¯ex coronary artery.
Values are expressed as mean+s.e.m for n=5 or six experiments.
Asterisks indicate a signi®cant increase in bleeding time compared to
respective baseline (P50.05).
British Journal of Pharmacology vol 136 (6)
In vivo antithrombotic activity of CRL42796J.K. Hennan et al934
known to occur clinically provides a reliable model for the
evaluation of antiplatelet agents for the prevention of
occlusive arterial thrombosis.
During the complex platelet response to vessel wall injury,
multiple mediators contribute to platelet activation and
aggregation including ®brinogen, thrombin, ADP, thrombox-
ane A2 and serotonin (Marcus, 1994). Conventional
antithrombotic agents such as aspirin, prostacyclin, throm-
boxane synthase inhibitors and thromboxane receptor
antagonists directly target single mediators of platelet
activation. Because the ®nal common pathway in thrombus
development involves platelets binding to ®brinogen via the
GPIIb/IIIa receptor, inhibition of this ®nal pathway provides
an eective antithrombotic eect that encompasses inhibition
of platelet activation in response to numerous platelet
agonists. The present study demonstrates the in vivo ecacy
of the platelet GPIIb/IIIa receptor antagonist CRL42796 in
an electrolytic injury model of the canine carotid and
coronary artery.
The intravenous threshold dose of CRL42796 for prevent-
ing arterial thrombosis required a loading dose of 15 mg kg71
followed by a continuous infusion of 0.31 mg kg71 min71 or
0.69 mg kg71 min71. Both infusion rates maintained vessel
patency with the higher rate being more eective. There was
a progressive decline in carotid artery blood ¯ow over the
course of the experiment with the lower infusion dose that
was not observed when the dose was increased. Thrombi
recovered from the vessels subjected to electrolytic injury
during treatment with CRL42796 were smaller than those
retrieved from control vessels which correlates well with the
inhibition of occlusive thrombus formation. However, these
results should be interpreted carefully as the thrombi in
control arteries were in situ for a longer period and had an
opportunity to increase in size. It is important to recall that
arterial thrombi propagate in a retrograde direction due to
the presence of an occlusive plug and stasis. The events
leading to thrombus propagation would be eliminated or
markedly reduced under conditions in which blood ¯ow is
maintained, albeit reduced, after treatment with an antiplate-
let agent.
Ex vivo platelet responses from citrate anticoagulated
whole blood were only partly correlated with the inhibition
of arterial thrombosis. The high and low infusion rate of
CRL42796 completely inhibited platelet responses as long as
the infusion was maintained; however, two of the ®ve vessels
tested at the lower infusion dose developed occlusive
thrombosis. Previous studies have indicated that citrated
whole blood platelet responses after treatment with GPIIb/
IIIa receptor antagonists do not correlate with the in vivo
prevention of arterial thrombosis (Phillips et al., 1997;
Rebello et al., 1998). The discrepancy between the in vitro
platelet aggregation responses conducted in the presence of
citrate and the in vivo results relates to a decrease in the
plasma ionized calcium concentration due to chelation with
citrate (Phillips et al., 1997; Rebello et al., 1998). Calcium is
essential for the formation of the GPIIb/IIIa heterodimer
complex (Lam, 1992) and for the interaction between the
GPIIb/IIIa receptor and ®brinogen (Steiner et al., 1989).
When the calcium concentration of platelet rich plasma is
decreased by citrate, binding of the GPIIb/IIIa receptor
antagonist is enhanced resulting in an overestimation of the
antiplatelet ecacy of the compound. In animals treated with
the lower infusion dose of CRL42796 (0.31 mg kg71 min71)
platelet responses in PRP prepared from heparin anti-
coagulated whole blood were reduced, but not signi®cantly
inhibited. With the lower infusion dose of CRL42796 40% of
the vessels occluded. Thus, it appears that ex vivo platelet
aggregation responses conducted in heparin anticoagulated
PRP are better correlated more dependably with the in vivo
observations on thrombosis. At the higher infusion dose of
CRL42796 (0.69 mg kg71 min71) platelet responses from
heparin anticoagulated PRP were signi®cantly reduced and
thrombus formation was prevented. Thus, eective anti-
thrombotic doses of GPIIb/IIIa receptor antagonists may be
extrapolated more accurately from ex vivo platelet aggrega-
tion responses performed in PRP in which the physiologic
concentration of ionized calcium is maintained.
An interesting aspect of the platelet inhibitory action of
CRL42796 was that it dissipated rapidly upon discontinuing
the drug infusion and vessels occluded within 60 min of
terminating the infusion (data not shown). Thus, CRL42796
displays a rapid-on and rapid-o pharmacological pro®le that
may oer an improved safety factor in those clinical
situations where increased bleeding might occur. Other
GPIIb/IIIa receptor antagonists such as 7E3 (Bates et al.,
1992; Rote et al., 1994c), DMP-728 (Lucchesi et al., 1994),
and SM-20302 (Huang et al., 1999) result in extended
maintenance of vessel patency despite the fact that ex vivo
platelet aggregation responses return to baseline values. There
are other factors to consider involving a time-dependent
decrease in the thrombogenicity of the injured vessel wall thus
allowing preservation of blood ¯ow in the presence of normal
platelet function. The pharmacokinetic pro®le of CRL42796
may be of value when used over a period of 24 ± 48 h to
provide sucient time for vessel wall `passivation' to occur
before terminating the infusion (Bates et al., 1992).
Bleeding times have been reported to be a poorly
reproducible determinant of platelet reactivity (Channing-
Rodgers & Levine, 1990). In the present study, tongue-
bleeding times correlated with the inhibition of platelet
activity and thrombosis. At the lower infusion dose of
CRL42796, we did not observe a signi®cant increase in
bleeding and occlusive thrombus formation was not pre-
vented completely. At the higher infusion dose, tongue-
bleeding time was increased signi®cantly and occlusive
thrombosis was inhibited. The results suggest that bleeding
time may be a useful measure for the ability of a platelet
receptor antagonist to inhibit arterial thrombosis.
The combination of CRL42796 and aspirin failed to
produce an additive or synergistic antithrombotic eect.
Aspirin was administered orally at 741 and 717 h before
commencing the experimental protocol. Aspirin is known to
irreversibly inhibit platelet derived COX-1 and to reversibly
inhibit the constitutive and inducible forms of endothelial
COX-2 (Vane, 1971).
We previously demonstrated that the dosing regimen for
aspirin as used in this study inhibits platelet responses to
arachidonic acid while allowing endothelial sources of COX-2
to regenerate and produce prostacyclin (Hennan et al., 2001).
Aspirin alone signi®cantly increased time to thrombosis in the
current study; however, it did not prevent occlusive arterial
thrombus formation. This result is consistent with those
observed previously in this laboratory using the same
experimental model and aspirin-dosing regimen (Hennan et
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al., 2001). When aspirin was combined with the low infusion
dose of CRL42796, no additional antithrombotic bene®t was
observed. Time to thrombosis remained relatively the same and
two of the ®ve vessels subjected to electrolytic injury occluded.
CRL42796 administered at the same dose in the absence of
aspirin resulted in occlusion in two of ®ve vessels. An analysis
of the carotid artery blood ¯ow in animals treated with aspirin
and CRL42796 revealed a rapid decline in ¯ow over the
180 min of electrolytic injury. In comparison to treatment with
CRL42796 alone, the addition of aspirin appeared to accelerate
the reduction in blood ¯ow that occurs in response to deep
vessel wall injury. The underlying mechanism to account for
this observation remains unknown and is deserving of further
study. It is interesting to note that bleeding times were
unchanged in the presence of aspirin and CRL42796, possibly
indicating a change in vascular tone in the tongue. On the other
hand, one might question the bene®t to be derived from the
addition of aspirin to a treatment regimen involving the use of
a platelet GPIIb/IIIa receptor antagonist. The antiplatelet
eect of aspirin is directed against the enzymatic conversion of
arachidonic acid to thromboxane A2 in which the latter serves
as an agonist for platelet aggregation. Aspirin does not prevent
platelet aggregation by other agonists present in vivo during
vessel wall injury. Furthermore, since activation of the GPIIb/
IIIa receptor is the ®nal common pathway for platelet
aggregation, it is unlikely that aspirin would serve as an
eective adjunctive agent.
In conclusion, CRL42796 eectively inhibits ex vivo
platelet aggregation in response to AA and ADP and only
marginally increases bleeding time. CRL42796 is an eective
in vivo intravenous antithrombotic agent for preventing
occlusive arterial thrombosis in response to deep vessel wall
injury when used as the sole intervention. Ex vivo platelet
aggregation responses conducted in the presence of a
physiologic plasma ionized calcium concentration is a more
accurate indicator of a drug's antithrombotic potential
compared to ex vivo studies done in PRP anticoagulated
with citrate. As the dose of CRL42796 is increased bleeding
time increases; however, careful control of the plasma
concentration may help to avoid excessive peak plasma levels
that contribute to excessive bleeding. The combination of low
dose CRL42796 with aspirin did not provide a further
bene®t. Furthermore, the addition of aspirin appears to
paradoxically reduce the ecacy of CRL42796. The mechan-
ism to account for this ®nding is not apparent and is
deserving of further investigation.
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